
Voyager Therapeutics (VYGR) Stock Forecast & Price Target
Voyager Therapeutics (VYGR) Analyst Ratings
Bulls say
Voyager Therapeutics Inc possesses a robust pipeline of potential gene therapies aimed at severe neurological diseases, emphasizing the significance of their TRACER platform for developing AAV-based gene therapies that may yield durable efficacy. The company's co-commercialization options for key programs could augment long-term revenue potential, while the favorable safety profile bolstered by the absence of serious adverse events supports a positive assessment of their clinical progress. Additionally, the extended cash runway into mid-2027, following adjustments in their development strategy, enables Voyager to focus on advancing its promising Alzheimer's programs, further enhancing the investment thesis for shareholders.
Bears say
Voyager Therapeutics Inc is currently not generating sales revenue and faces significant challenges, as it may take many years for the company to achieve profitability, highlighted by a reported net loss of ($1.13) per basic and diluted share for the year. The company is exposed to regulatory and clinical risks, as any failure in producing sufficient products for clinical studies, delays in approval, or unfavorable study outcomes could adversely impact revenue projections and overall valuation estimates. Furthermore, Voyager's competitive position is precarious, with multiple tau antibody programs ahead of its candidate VY7523, requiring a strong efficacy and safety profile to capture market share, amid the inherent risks of clinical trial failures and slow enrollment.
This aggregate rating is based on analysts' research of Voyager Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Voyager Therapeutics (VYGR) Analyst Forecast & Price Prediction
Start investing in Voyager Therapeutics (VYGR)
Order type
Buy in
Order amount
Est. shares
0 shares